Bayer (Germany)

Aggregation framework for continuous digital health measures and application to walking activity data

Abstract No standardized procedures for aggregating continuous digital health measures exist. Using a modified Delphi approach, we developed a framework to standardize the selection of aggregations that provide clinically meaningful, stable values. This was applied to aggregate s...

Practical Computational Exploration of Chemical Reaction Space: Assessing the Chemical Stability of Active Pharmaceutical Ingredients Under Acidic Conditions

ABSTRACT Understanding the chemical degradation of active pharmaceutical ingredients is critical for formulation development and regulatory compliance, yet computational tools either rely on predefined reaction rules that limit discovery of unanticipated pathways or cannot distin...

Tearing Down Scientific Boundaries: Frontiers in Medicinal Chemistry 2026

The Frontiers in Medicinal Chemistry (FiMC) was held in Münster from March 24 th to 27 th as the largest international Medicinal Chemistry conference in Germany. Welcoming more than 240 participants from around 20 countries, it was a vibrant conference, celebrating the community...

History of worsening heart failure and outcomes with vericiguat in ambulatory HFrEF: an exploratory post-hoc analysis of VICTOR

Stefan Störk, Javed Butler, Caroline Morbach, Fabian Kerwagen, Johann Bauersachs, Ephraim B Winzer, Justin Ezekowitz, Carolyn S P Lam, Inga Bayh, Stefan He

The importance of phenmedipham for European agriculture: a determination of essential uses for post-emergence weed control in sugar beet

Abstract Phenmedipham has been used for weed management in European sugar beet for decades and is undergoing renewal evaluation. We evaluated its agronomic importance to demonstrate its critical role in European agriculture. Systematic evaluation across eight EU Member States rep...

Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice

Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study, ATTRibute-CM (NCT03860935). To complement trial data, ACO-REAL (NCT07235462) was des...